Literature DB >> 21618496

Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria.

A N Gordon-Weeks1, A Snaith, T Petrinic, P J Friend, A Burls, M A Silva.   

Abstract

BACKGROUND: The aim of this systematic review was to assess the evidence on tumour downstaging before liver transplantation in patients with hepatocellular carcinoma (HCC) initially staged beyond the Milan criteria.
METHODS: MEDLINE (from 1952), Embase (from 1980) and the Cochrane Library were searched. The review included cohort studies that reported the outcomes of patients with HCC outside the Milan criteria who underwent downstaging before transplantation.
RESULTS: Eight studies met the inclusion criteria and included a total of 720 patients who underwent transplantation following downstaging after initial presentation with disease outside the Milan criteria. The rate of successful downstaging varied from 24 to 69 per cent of patients. Reported survival rates ranged from 82 to 100 per cent, 79 to 100 per cent and 54·6 to 94 per cent at 1, 3 and 5 years respectively. These were comparable with results for patients presenting within the Milan criteria.
CONCLUSION: Successful downstaging of HCC to within the Milan criteria is feasible in a proportion of patients. Absolute and disease-free survival rates in patients transplanted following downstaging are comparable to those in patients within the Milan criteria.
Copyright © 2011 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21618496     DOI: 10.1002/bjs.7561

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  27 in total

1.  Role of operative therapy in non-cirrhotic patients with metastatic hepatocellular carcinoma.

Authors:  Victor Zaydfudim; Rory L Smoot; Clancy J Clark; Michael L Kendrick; Florencia G Que; Michael B Farnell; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2012-05-30       Impact factor: 3.452

Review 2.  Hepatocellular carcinoma review: current treatment, and evidence-based medicine.

Authors:  Ali Raza; Gagan K Sood
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Milan criteria, multi-nodularity, and microvascular invasion predict the recurrence patterns of hepatocellular carcinoma after resection.

Authors:  Hung-Hsu Hung; Hao-Jan Lei; Gar-Yang Chau; Chien-Wei Su; Cheng-Yuan Hsia; Wei-Yu Kao; Wing-Yiu Lui; Wen-Chieh Wu; Han-Chieh Lin; Jaw-Ching Wu
Journal:  J Gastrointest Surg       Date:  2012-12-06       Impact factor: 3.452

Review 4.  Radioembolization for hepatocellular carcinoma: current role and future directions - the medical oncologist's perspective.

Authors:  Peter Gibbs; Jeanne Tie; Lourens Bester
Journal:  Hepat Oncol       Date:  2015-04-20

5.  Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.

Authors:  Rajesh Ramanathan; Amit Sharma; David D Lee; Martha Behnke; Karen Bornstein; R Todd Stravitz; Malcolm Sydnor; Ann Fulcher; Adrian Cotterell; Marc P Posner; Robert A Fisher
Journal:  Transplantation       Date:  2014-07-15       Impact factor: 4.939

Review 6.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

7.  Advances and Future Directions in the Treatment of Hepatocellular Carcinoma.

Authors:  Ashil J Gosalia; Paul Martin; Patricia D Jones
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-07

Review 8.  Advances in managing hepatocellular carcinoma.

Authors:  Marielle Reataza; David K Imagawa
Journal:  Front Med       Date:  2014-05-08       Impact factor: 4.592

9.  Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria.

Authors:  Jianyong Lei; Wentao Wang; Lunan Yan
Journal:  J Gastrointest Surg       Date:  2013-05-30       Impact factor: 3.452

10.  Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.

Authors:  Ming-Rong Cheng; Qing Li; Tao Wan; Bing He; Jiang Han; Hou-Xiang Chen; Feng-Xiao Yang; Wei Wang; Hong-Zhi Xu; Tao Ye; Bing-Bing Zha
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.